{"id":411756,"date":"2021-01-11T07:08:10","date_gmt":"2021-01-11T12:08:10","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=411756"},"modified":"2021-01-11T07:08:10","modified_gmt":"2021-01-11T12:08:10","slug":"helius-medical-technologies-inc-submits-response-to-u-s-fda-in-pursuit-of-de-novo-classification-and-clearance-of-the-pons-device-for-the-treatment-of-gait-deficit-due-to-symptoms-of-multi","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-submits-response-to-u-s-fda-in-pursuit-of-de-novo-classification-and-clearance-of-the-pons-device-for-the-treatment-of-gait-deficit-due-to-symptoms-of-multi\/","title":{"rendered":"Helius Medical Technologies, Inc. Submits Response to U.S. FDA in Pursuit of De Novo Classification and Clearance of the PoNS\u2122 Device for the Treatment of Gait Deficit Due to Symptoms of Multiple Sclerosis"},"content":{"rendered":"

\nSubmits formal response to the U.S. Food and Drug Administration\u2019s request for additional information
\n<\/h2>\n
\n

NEWTOWN, Pa., Jan. 11, 2021 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (\u201cHelius\u201d or the \u201cCompany\u201d), a neurotech company focused on neurological wellness, today announced that it has submitted its formal response to the U.S. Food and Drug Administration\u2019s (the \u201cFDA\u201d or \u201cAgency\u201d) request for additional information.<\/p>\n

The FDA\u2019s request for additional information was related to the Company\u2019s request for de novo classification and clearance of the Portable Neuromodulation Stimulator (PoNS\u2122) device as a potential treatment for gait deficit due to symptoms of Multiple Sclerosis (\u201cMS\u201d), to be used as an adjunct to a supervised therapeutic exercise program in patients over 18 years of age.<\/p>\n

\u201cThe Helius team is very excited to announce the timely submission of our response to the FDA\u2019s request for additional information,\u201d said Dane Andreeff, Interim President and Chief Executive Officer of Helius. \u201cThe achievement of this important milestone was made possible by the diligent efforts of our regulatory and clinical affairs team, and I would like to thank them for their hard work and dedication in recent months.\u201d<\/p>\n

Mr. Andreeff continued: \u201cLooking ahead, we expect that the FDA\u2019s receipt of our response will enable the FDA to resume its review of our request for de novo classification and clearance. We remain committed to our goal of bringing our PoNS technology to the aid of U.S. patients suffering with gait deficit due to MS-related symptoms as expeditiously as possible, and hope to receive the FDA\u2019s decision on our request for de novo classification and clearance during the first half of this year.\u201d<\/p>\n

\n Additional Background Information:<\/u>\n <\/p>\n

Helius submitted its request for de novo classification and clearance of the PoNS device for the treatment of gait deficit due to symptoms from MS on August 4, 2020, following the receipt of Breakthrough Designation by FDA in early May. On October 19, 2020, the Company announced the receipt of the FDA\u2019s request for additional information, which was received approximately 75 days following the submission date and placed the FDA\u2019s review on hold until receipt by the FDA of the requested information.<\/p>\n

\n About Helius Medical Technologies, Inc.<\/strong>\n <\/p>\n

Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company\u2019s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain\u2019s ability to heal itself. The Company\u2019s first commercial product is the Portable Neuromodulation Stimulator (PoNSTM<\/sup>). For more information, visit\u00a0www.heliusmedical.com<\/a>.<\/p>\n

\n About the PoNS\u2122 Device and PoNS Treatment\u2122<\/strong>\n <\/p>\n

The Portable Neuromodulation Stimulator (PoNS\u2122) is authorized for sale in Canada as a class II, non-implantable, medical device intended as a short term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from multiple sclerosis (MS), and chronic balance deficit due to mild-to-moderate traumatic brain injury (mmTBI) and is to be used in conjunction with physical therapy. The PoNS\u2122 is an investigational medical device in the United States, the European Union (\u201cEU\u201d), and Australia (\u201cAUS\u201d). The device is currently under review for de novo classification and clearance by the FDA. It is also under premarket review by the AUS Therapeutic Goods Administration. PoNS\u2122 is currently not commercially available in the United States, the European Union or Australia.<\/p>\n

\n Investor Relations Contact:<\/strong>\n <\/p>\n

Westwicke Partners on behalf of Helius Medical Technologies, Inc.
Jack Powell
investorrelations@heliusmedical.com<\/a><\/p>\n

\n Cautionary Disclaimer Statement:\u00a0<\/strong>\n <\/p>\n

Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by terms such as \u201cbelieve,\u201d \u201ccontinue,\u201d \u201clook forward,\u201d \u201cwill,\u201d \u201ccommitted to,\u201d \u201cgoal,\u201d \u201cexpect,\u201d \u201cremain,\u201d \u201chope\u201d and similar expressions. Such forward-looking statements include, among others, statements regarding the Company\u2019s future growth and operational progress, clinical and regulatory development plans for the PoNS device, and potential regulatory clearance of the PoNS device, including expected timing for the FDA to resume its review of our request for de novo classification and clearance and expected timing for receipt of the FDA\u2019s decision on such request.<\/p>\n

These statements involve substantial known and unknown risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those expressed or implied by such statements. Important factors that could cause actual results to differ materially from the Company\u2019s expectations include uncertainties associated with the clinical development process and FDA regulatory submission and approval process, including that the Company\u2019s request for de novo classification and clearance may be declined by the FDA, that the FDA is not required to and may not respond to the Company\u2019s request in the timeframe indicated by its de novo review goals or in the time the Company expects, whether the Company\u2019s response will be satisfactory to the FDA, whether the FDA will require additional information, whether the Company will be able to provide it in a timely manner and whether such additional information will be satisfactory to the FDA, uncertainties regarding the Company\u2019s capital requirements to achieve its business objectives, the impact of the COVID-19 pandemic, uncertainties associated with future clinical trials and other development activities, and other risks detailed from time to time in the filings made by the Company with securities regulators, including the risks and uncertainties described in the \u201cRisk Factors\u201d sections of the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2019, Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 and its other filings with the United States Securities and Exchange Commission and the Canadian securities regulators, which can be obtained from either at www.sec.gov or www.sedar.com.The reader is cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law.<\/p>\n

The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.\u00a0<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Submits formal response to the U.S. Food and Drug Administration\u2019s request for additional information NEWTOWN, Pa., Jan. 11, 2021 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (\u201cHelius\u201d or the \u201cCompany\u201d), a neurotech company focused on neurological wellness, today announced that it has submitted its formal response to the U.S. Food and Drug Administration\u2019s (the \u201cFDA\u201d or \u201cAgency\u201d) request for additional information. The FDA\u2019s request for additional information was related to the Company\u2019s request for de novo classification and clearance of the Portable Neuromodulation Stimulator (PoNS\u2122) device as a potential treatment for gait deficit due to symptoms of Multiple Sclerosis (\u201cMS\u201d), to be used as an adjunct to a supervised therapeutic exercise program in patients over 18 years of … <\/p>\n

Continue reading “Helius Medical Technologies, Inc. Submits Response to U.S. FDA in Pursuit of De Novo Classification and Clearance of the PoNS\u2122 Device for the Treatment of Gait Deficit Due to Symptoms of Multiple Sclerosis”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-411756","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nHelius Medical Technologies, Inc. Submits Response to U.S. FDA in Pursuit of De Novo Classification and Clearance of the PoNS\u2122 Device for the Treatment of Gait Deficit Due to Symptoms of Multiple Sclerosis - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-submits-response-to-u-s-fda-in-pursuit-of-de-novo-classification-and-clearance-of-the-pons-device-for-the-treatment-of-gait-deficit-due-to-symptoms-of-multi\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Helius Medical Technologies, Inc. Submits Response to U.S. FDA in Pursuit of De Novo Classification and Clearance of the PoNS\u2122 Device for the Treatment of Gait Deficit Due to Symptoms of Multiple Sclerosis - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Submits formal response to the U.S. Food and Drug Administration\u2019s request for additional information NEWTOWN, Pa., Jan. 11, 2021 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (\u201cHelius\u201d or the \u201cCompany\u201d), a neurotech company focused on neurological wellness, today announced that it has submitted its formal response to the U.S. Food and Drug Administration\u2019s (the \u201cFDA\u201d or \u201cAgency\u201d) request for additional information. The FDA\u2019s request for additional information was related to the Company\u2019s request for de novo classification and clearance of the Portable Neuromodulation Stimulator (PoNS\u2122) device as a potential treatment for gait deficit due to symptoms of Multiple Sclerosis (\u201cMS\u201d), to be used as an adjunct to a supervised therapeutic exercise program in patients over 18 years of … Continue reading "Helius Medical Technologies, Inc. Submits Response to U.S. FDA in Pursuit of De Novo Classification and Clearance of the PoNS\u2122 Device for the Treatment of Gait Deficit Due to Symptoms of Multiple Sclerosis"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-submits-response-to-u-s-fda-in-pursuit-of-de-novo-classification-and-clearance-of-the-pons-device-for-the-treatment-of-gait-deficit-due-to-symptoms-of-multi\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-11T12:08:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzQyMiMzOTEyMTc3IzIwODIwMzE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-submits-response-to-u-s-fda-in-pursuit-of-de-novo-classification-and-clearance-of-the-pons-device-for-the-treatment-of-gait-deficit-due-to-symptoms-of-multi\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-submits-response-to-u-s-fda-in-pursuit-of-de-novo-classification-and-clearance-of-the-pons-device-for-the-treatment-of-gait-deficit-due-to-symptoms-of-multi\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Helius Medical Technologies, Inc. Submits Response to U.S. FDA in Pursuit of De Novo Classification and Clearance of the PoNS\u2122 Device for the Treatment of Gait Deficit Due to Symptoms of Multiple Sclerosis\",\"datePublished\":\"2021-01-11T12:08:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-submits-response-to-u-s-fda-in-pursuit-of-de-novo-classification-and-clearance-of-the-pons-device-for-the-treatment-of-gait-deficit-due-to-symptoms-of-multi\\\/\"},\"wordCount\":1108,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-submits-response-to-u-s-fda-in-pursuit-of-de-novo-classification-and-clearance-of-the-pons-device-for-the-treatment-of-gait-deficit-due-to-symptoms-of-multi\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMzQyMiMzOTEyMTc3IzIwODIwMzE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-submits-response-to-u-s-fda-in-pursuit-of-de-novo-classification-and-clearance-of-the-pons-device-for-the-treatment-of-gait-deficit-due-to-symptoms-of-multi\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-submits-response-to-u-s-fda-in-pursuit-of-de-novo-classification-and-clearance-of-the-pons-device-for-the-treatment-of-gait-deficit-due-to-symptoms-of-multi\\\/\",\"name\":\"Helius Medical Technologies, Inc. Submits Response to U.S. FDA in Pursuit of De Novo Classification and Clearance of the PoNS\u2122 Device for the Treatment of Gait Deficit Due to Symptoms of Multiple Sclerosis - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-submits-response-to-u-s-fda-in-pursuit-of-de-novo-classification-and-clearance-of-the-pons-device-for-the-treatment-of-gait-deficit-due-to-symptoms-of-multi\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-submits-response-to-u-s-fda-in-pursuit-of-de-novo-classification-and-clearance-of-the-pons-device-for-the-treatment-of-gait-deficit-due-to-symptoms-of-multi\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMzQyMiMzOTEyMTc3IzIwODIwMzE=\",\"datePublished\":\"2021-01-11T12:08:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-submits-response-to-u-s-fda-in-pursuit-of-de-novo-classification-and-clearance-of-the-pons-device-for-the-treatment-of-gait-deficit-due-to-symptoms-of-multi\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-submits-response-to-u-s-fda-in-pursuit-of-de-novo-classification-and-clearance-of-the-pons-device-for-the-treatment-of-gait-deficit-due-to-symptoms-of-multi\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-submits-response-to-u-s-fda-in-pursuit-of-de-novo-classification-and-clearance-of-the-pons-device-for-the-treatment-of-gait-deficit-due-to-symptoms-of-multi\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMzQyMiMzOTEyMTc3IzIwODIwMzE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMzQyMiMzOTEyMTc3IzIwODIwMzE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-submits-response-to-u-s-fda-in-pursuit-of-de-novo-classification-and-clearance-of-the-pons-device-for-the-treatment-of-gait-deficit-due-to-symptoms-of-multi\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Helius Medical Technologies, Inc. Submits Response to U.S. FDA in Pursuit of De Novo Classification and Clearance of the PoNS\u2122 Device for the Treatment of Gait Deficit Due to Symptoms of Multiple Sclerosis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Helius Medical Technologies, Inc. Submits Response to U.S. FDA in Pursuit of De Novo Classification and Clearance of the PoNS\u2122 Device for the Treatment of Gait Deficit Due to Symptoms of Multiple Sclerosis - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-submits-response-to-u-s-fda-in-pursuit-of-de-novo-classification-and-clearance-of-the-pons-device-for-the-treatment-of-gait-deficit-due-to-symptoms-of-multi\/","og_locale":"en_US","og_type":"article","og_title":"Helius Medical Technologies, Inc. Submits Response to U.S. FDA in Pursuit of De Novo Classification and Clearance of the PoNS\u2122 Device for the Treatment of Gait Deficit Due to Symptoms of Multiple Sclerosis - Market Newsdesk","og_description":"Submits formal response to the U.S. Food and Drug Administration\u2019s request for additional information NEWTOWN, Pa., Jan. 11, 2021 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (\u201cHelius\u201d or the \u201cCompany\u201d), a neurotech company focused on neurological wellness, today announced that it has submitted its formal response to the U.S. Food and Drug Administration\u2019s (the \u201cFDA\u201d or \u201cAgency\u201d) request for additional information. The FDA\u2019s request for additional information was related to the Company\u2019s request for de novo classification and clearance of the Portable Neuromodulation Stimulator (PoNS\u2122) device as a potential treatment for gait deficit due to symptoms of Multiple Sclerosis (\u201cMS\u201d), to be used as an adjunct to a supervised therapeutic exercise program in patients over 18 years of … Continue reading \"Helius Medical Technologies, Inc. Submits Response to U.S. FDA in Pursuit of De Novo Classification and Clearance of the PoNS\u2122 Device for the Treatment of Gait Deficit Due to Symptoms of Multiple Sclerosis\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-submits-response-to-u-s-fda-in-pursuit-of-de-novo-classification-and-clearance-of-the-pons-device-for-the-treatment-of-gait-deficit-due-to-symptoms-of-multi\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-11T12:08:10+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzQyMiMzOTEyMTc3IzIwODIwMzE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-submits-response-to-u-s-fda-in-pursuit-of-de-novo-classification-and-clearance-of-the-pons-device-for-the-treatment-of-gait-deficit-due-to-symptoms-of-multi\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-submits-response-to-u-s-fda-in-pursuit-of-de-novo-classification-and-clearance-of-the-pons-device-for-the-treatment-of-gait-deficit-due-to-symptoms-of-multi\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Helius Medical Technologies, Inc. Submits Response to U.S. FDA in Pursuit of De Novo Classification and Clearance of the PoNS\u2122 Device for the Treatment of Gait Deficit Due to Symptoms of Multiple Sclerosis","datePublished":"2021-01-11T12:08:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-submits-response-to-u-s-fda-in-pursuit-of-de-novo-classification-and-clearance-of-the-pons-device-for-the-treatment-of-gait-deficit-due-to-symptoms-of-multi\/"},"wordCount":1108,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-submits-response-to-u-s-fda-in-pursuit-of-de-novo-classification-and-clearance-of-the-pons-device-for-the-treatment-of-gait-deficit-due-to-symptoms-of-multi\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzQyMiMzOTEyMTc3IzIwODIwMzE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-submits-response-to-u-s-fda-in-pursuit-of-de-novo-classification-and-clearance-of-the-pons-device-for-the-treatment-of-gait-deficit-due-to-symptoms-of-multi\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-submits-response-to-u-s-fda-in-pursuit-of-de-novo-classification-and-clearance-of-the-pons-device-for-the-treatment-of-gait-deficit-due-to-symptoms-of-multi\/","name":"Helius Medical Technologies, Inc. Submits Response to U.S. FDA in Pursuit of De Novo Classification and Clearance of the PoNS\u2122 Device for the Treatment of Gait Deficit Due to Symptoms of Multiple Sclerosis - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-submits-response-to-u-s-fda-in-pursuit-of-de-novo-classification-and-clearance-of-the-pons-device-for-the-treatment-of-gait-deficit-due-to-symptoms-of-multi\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-submits-response-to-u-s-fda-in-pursuit-of-de-novo-classification-and-clearance-of-the-pons-device-for-the-treatment-of-gait-deficit-due-to-symptoms-of-multi\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzQyMiMzOTEyMTc3IzIwODIwMzE=","datePublished":"2021-01-11T12:08:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-submits-response-to-u-s-fda-in-pursuit-of-de-novo-classification-and-clearance-of-the-pons-device-for-the-treatment-of-gait-deficit-due-to-symptoms-of-multi\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-submits-response-to-u-s-fda-in-pursuit-of-de-novo-classification-and-clearance-of-the-pons-device-for-the-treatment-of-gait-deficit-due-to-symptoms-of-multi\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-submits-response-to-u-s-fda-in-pursuit-of-de-novo-classification-and-clearance-of-the-pons-device-for-the-treatment-of-gait-deficit-due-to-symptoms-of-multi\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzQyMiMzOTEyMTc3IzIwODIwMzE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzQyMiMzOTEyMTc3IzIwODIwMzE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-submits-response-to-u-s-fda-in-pursuit-of-de-novo-classification-and-clearance-of-the-pons-device-for-the-treatment-of-gait-deficit-due-to-symptoms-of-multi\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Helius Medical Technologies, Inc. Submits Response to U.S. FDA in Pursuit of De Novo Classification and Clearance of the PoNS\u2122 Device for the Treatment of Gait Deficit Due to Symptoms of Multiple Sclerosis"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/411756","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=411756"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/411756\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=411756"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=411756"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=411756"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}